• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

4318名美国慢性丙型肝炎病毒感染退伍军人的丙型肝炎治疗候选资格及治疗结果:注射吸毒史有影响吗?

Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?

作者信息

Seal Karen H, Currie Sue L, Shen Hui, Anand Bhupinderjit S, Bini Edmund J, Brau Norbert, Jeffers Lennox, Wright Teresa L

机构信息

VA Medical Center, San Francisco, CA 94121, USA.

出版信息

J Clin Gastroenterol. 2007 Feb;41(2):199-205. doi: 10.1097/01.mcg.0000212644.82853.51.

DOI:10.1097/01.mcg.0000212644.82853.51
PMID:17245220
Abstract

BACKGROUND/GOALS: Many patients with a history of injection drug use (IDU) are excluded from hepatitis C virus (HCV) treatment. This prospective multicenter study aimed to determine the impact of IDU history on HCV treatment candidacy and outcomes.

STUDY

Between 1999 and 2001, 4318 HCV-infected patients seen at 24 VA Medical Centers were evaluated for HCV treatment candidacy and followed prospectively. Univariate and multivariate logistic regression analyses were used to determine whether an IDU history was associated with HCV treatment candidacy, HCV treatment acceptance, early treatment discontinuation, and virologic response.

RESULTS

Of 4318 participants, 2611 (61%) reported an IDU history. IDU history was not significantly associated with HCV treatment candidacy, acceptance, early discontinuation of therapy, or virologic response (all P values nonsignificant). Instead, reduced HCV treatment candidacy was independently associated with low-income [odds ratio (OR)=1.46, 95% confidence interval (CI)=1.22-1.74), education < or = 12 years (OR=1.23, 95% CI=1.03-1.46), and alcohol consumption > or = 3 drinks/d (OR=2.08, 95% CI=1.68-2.57), whereas early discontinuation of HCV therapy was independently associated with low-income and consuming > or = 3 alcoholic drinks/d.

CONCLUSIONS

A history of IDU was not associated with HCV treatment candidacy or outcomes, supporting national guidelines to evaluate former IDUs on a case-by-case basis for HCV treatment.

摘要

背景/目标:许多有注射吸毒史(IDU)的患者被排除在丙型肝炎病毒(HCV)治疗之外。这项前瞻性多中心研究旨在确定IDU病史对HCV治疗候选资格和治疗结果的影响。

研究

在1999年至2001年期间,对在24家退伍军人事务医疗中心就诊的4318例HCV感染患者进行了HCV治疗候选资格评估,并进行了前瞻性随访。采用单因素和多因素逻辑回归分析来确定IDU病史是否与HCV治疗候选资格、HCV治疗接受情况、早期治疗中断和病毒学应答相关。

结果

在4318名参与者中,2611名(61%)报告有IDU病史。IDU病史与HCV治疗候选资格、接受情况、早期治疗中断或病毒学应答均无显著相关性(所有P值均无统计学意义)。相反,HCV治疗候选资格降低与低收入独立相关[比值比(OR)=1.46,95%置信区间(CI)=1.22-1.74]、教育程度≤12年(OR=1.23,95%CI=1.03-1.46)以及饮酒量≥3杯/天(OR=2.08,95%CI=1.68-2.57),而HCV治疗的早期中断与低收入和饮酒量≥3杯/天独立相关。

结论

IDU病史与HCV治疗候选资格或治疗结果无关,支持国家指南对既往有IDU史的患者逐案评估HCV治疗。

相似文献

1
Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?4318名美国慢性丙型肝炎病毒感染退伍军人的丙型肝炎治疗候选资格及治疗结果:注射吸毒史有影响吗?
J Clin Gastroenterol. 2007 Feb;41(2):199-205. doi: 10.1097/01.mcg.0000212644.82853.51.
2
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.对4084名美国慢性丙型肝炎病毒感染退伍军人进行抗病毒治疗资格的前瞻性多中心研究。
Am J Gastroenterol. 2005 Aug;100(8):1772-9. doi: 10.1111/j.1572-0241.2005.41860.x.
3
Treatment for hepatitis C virus infection among current injection drug users in Australia.澳大利亚当前注射吸毒者丙型肝炎病毒感染的治疗
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9. doi: 10.1086/427448.
4
Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.精神疾病共病无法预测丙型肝炎血清学阳性退伍军人的干扰素治疗完成率。
J Clin Gastroenterol. 2007 Mar;41(3):322-8. doi: 10.1097/01.mcg.0000225629.22286.96.
5
Molecular epidemiology of hepatitis C infection in U.S. veteran liver transplant recipients: evidence for decreasing relative prevalence of genotype 1B.美国退伍军人肝移植受者丙型肝炎感染的分子流行病学:1B基因型相对流行率下降的证据。
Am J Gastroenterol. 1999 Oct;94(10):3015-9. doi: 10.1111/j.1572-0241.1999.01456.x.
6
Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.
Clin Infect Dis. 2006 Mar 1;42(5):669-72. doi: 10.1086/499951. Epub 2006 Jan 20.
7
Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study.患者、医疗服务提供者和医疗机构因素对退伍军人丙型肝炎病毒治疗的影响:一项全国性研究。
Am J Gastroenterol. 2011 Mar;106(3):483-91. doi: 10.1038/ajg.2010.430. Epub 2010 Nov 9.
8
Limited success of HCV antiviral therapy in United States veterans.美国退伍军人中丙型肝炎病毒抗病毒治疗的成效有限。
Am J Gastroenterol. 2002 Jan;97(1):149-55. doi: 10.1111/j.1572-0241.2002.05439.x.
9
Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study.接受阿片类药物替代疗法的注射吸毒者的丙型肝炎病毒治疗:一项前瞻性多中心研究。
Eur J Gastroenterol Hepatol. 2007 Aug;19(8):731-2. doi: 10.1097/01.meg.0000280175.79379.04.
10
Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?药物依赖患者慢性丙型肝炎的治疗:是时候改变规则了吗?
Addiction. 2004 Sep;99(9):1167-75. doi: 10.1111/j.1360-0443.2004.00821.x.

引用本文的文献

1
Hepatitis C viral infection in drug users.吸毒者中的丙型肝炎病毒感染
Clin Liver Dis (Hoboken). 2012 Jul 23;1(3):81-83. doi: 10.1002/cld.72. eCollection 2012 Jul.
2
Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.在退伍军人事务部丙型肝炎队列研究HCV-002中,2211名接受干扰素-α治疗的患者总体生存率有所提高,尽管无应答者中肝硬化发生率有所上升。
Dig Dis Sci. 2016 Jun;61(6):1744-56. doi: 10.1007/s10620-016-4122-5. Epub 2016 Apr 8.
3
Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond?
“现实世界”中的丙型肝炎病毒治疗:“真实”患者的治疗效果如何?
J Clin Exp Hepatol. 2014 Sep;4(3):214-20. doi: 10.1016/j.jceh.2014.07.003. Epub 2014 Jul 25.
4
The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan.终身药物使用对综合医疗保健计划中参保成员丙型肝炎治疗效果的影响。
Drug Alcohol Depend. 2014 Jan 1;134:222-227. doi: 10.1016/j.drugalcdep.2013.10.001. Epub 2013 Oct 12.
5
Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.直接作用抗病毒药物治疗时代的吸毒人群丙型肝炎病毒/人类免疫缺陷病毒合并感染的管理。
Clin Infect Dis. 2013 Aug;57 Suppl 2(Suppl 2):S118-24. doi: 10.1093/cid/cit326.
6
Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.医疗服务提供者向HIV合并感染患者推荐丙肝治疗的决策与提供者及患者的相关因素
J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug;11(4):245-51. doi: 10.1177/1545109712444163. Epub 2012 May 7.
7
Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection.慢性丙型肝炎病毒感染患者治疗起始与完成的模式及预测因素
Patient Prefer Adherence. 2012;6:285-95. doi: 10.2147/PPA.S30111. Epub 2012 Apr 4.
8
Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.注射毒品者接受丙型肝炎治疗的障碍:误区与证据。
Hepat Mon. 2011 Jul;11(7):513-8.
9
Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.医生对治疗丙型肝炎注射吸毒者的态度和做法:加拿大全国专家调查结果
Can J Gastroenterol. 2011 Mar;25(3):135-9. doi: 10.1155/2011/810108.
10
Racial differences in hepatitis C treatment eligibility.种族差异对丙型肝炎治疗资格的影响。
Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358.